Search Results

You are looking at 1 - 3 of 3 items for

  • Author: Y Shimomura x
  • Refine by access: All content x
Clear All Modify Search
H. Shimizu
Search for other papers by H. Shimizu in
Google Scholar
PubMed
Close
,
Y. Uehara
Search for other papers by Y. Uehara in
Google Scholar
PubMed
Close
,
Y. Tanaka
Search for other papers by Y. Tanaka in
Google Scholar
PubMed
Close
,
Y. Shimomura
Search for other papers by Y. Shimomura in
Google Scholar
PubMed
Close
, and
I. Kobayashi
Search for other papers by I. Kobayashi in
Google Scholar
PubMed
Close

ABSTRACT

Evidence is accumulating that adrenal steroids may be involved in the metabolic effects of cytokines. We evaluated the possible involvement of glucocorticoids in the inhibition of pancreatic insulin secretion by interleukin-1β (IL-1β), one of the cytokines produced by inflammatory cells. In the first group of experiments, adrenalectomized rats showed a significant reduction in basal and glucose (0·5 g/kg, i.v.)-stimulated immunoreactive insulin (IRI) levels after injection of IL-1β (1·0 μg/kg), but intact rats did not. Pretreatment with IL-1β increased plasma glucose levels 2 and 15 min after an i.v. bolus of glucose in adrenalectomized rats. In the second group of experiments, dexamethasone supplement (0·1 mg/kg) given to adrenalectomized rats cancelled the reduction in plasma glucose levels by IL-1β, and rats treated with 1·0 mg dexamethasone/kg showed a significant increase in basal IRI levels and enhanced serum IRI levels after IL-1β injection. However, 1·0 mg deoxycorticosterone/kg given daily for 7 days failed to cancel the effect of IL-1β on the reduction of serum IRI levels, although it attenuated the weight loss after adrenalectomy. The data suggested that withdrawal of glucocorticoids after adrenalectomy potentiates the effect of IL-1β on the reduction of serum IRI levels. Glucocorticoids may have a protective action against the reduction of serum IRI levels by IL-1β.

Journal of Endocrinology (1992) 132, 419–423

Restricted access
H Shimizu
Search for other papers by H Shimizu in
Google Scholar
PubMed
Close
,
Y Shimomura
Search for other papers by Y Shimomura in
Google Scholar
PubMed
Close
,
Y Nakanishi
Search for other papers by Y Nakanishi in
Google Scholar
PubMed
Close
,
T Futawatari
Search for other papers by T Futawatari in
Google Scholar
PubMed
Close
,
K Ohtani
Search for other papers by K Ohtani in
Google Scholar
PubMed
Close
,
N Sato
Search for other papers by N Sato in
Google Scholar
PubMed
Close
, and
M Mori
Search for other papers by M Mori in
Google Scholar
PubMed
Close

Abstract

The decrease in estrogen in menopausal women increases body fat. The present studies were undertaken to investigate the involvement of estrogen in leptin production in vivo. In the first study, expression of ob gene mRNA in white adipose tissue was measured at 2 and 8 weeks after ovariectomy in rats. In the second, serum leptin concentration was measured in total body fat of 87 weight-matched human subjects (29 men, 29 premenopausal and 29 postmenopausal women). In the third, changes in serum leptin concentration with the menstrual cycle were determined, ob gene expression decreased in subcutaneous and retroperitoneal white adipose tissue of ovariectomized rats 8 weeks after the operation, while ovariectomy increased ob gene expression in mesenteric white adipose tissue. Serum leptin concentration was decreased by ovariectomy. Estradiol supplement reversed the effect of ovariectomy on ob gene expression and circulating leptin levels. In humans, serum leptin concentration was higher in premenopausal women than in men, and in postmenopausal women it was lower than in premenopausal women, but still higher than in men. In 13 premenopausal women, serum leptin levels were significantly higher in the luteal phase than in the follicular phase. The present studies strongly indicate that estrogen regulates leptin production in rats and human subjects in vivo. Regional variation in the regulation of ob gene expression by estrogen was found.

Journal of Endocrinology (1997) 154, 285–292

Restricted access
M S Mondal Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Kiyotake, Miyazaki 889-1692, Japan
Department of Anatomy, Showa University School of Medicine, Tokyo 142-8555, Japan
Discovery Research Laboratories, Pharmaceuticals Research Division, Takeda Chemical Industries, Ibaraki 300-4293, Japan

Search for other papers by M S Mondal in
Google Scholar
PubMed
Close
,
H Yamaguchi Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Kiyotake, Miyazaki 889-1692, Japan
Department of Anatomy, Showa University School of Medicine, Tokyo 142-8555, Japan
Discovery Research Laboratories, Pharmaceuticals Research Division, Takeda Chemical Industries, Ibaraki 300-4293, Japan

Search for other papers by H Yamaguchi in
Google Scholar
PubMed
Close
,
Y Date Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Kiyotake, Miyazaki 889-1692, Japan
Department of Anatomy, Showa University School of Medicine, Tokyo 142-8555, Japan
Discovery Research Laboratories, Pharmaceuticals Research Division, Takeda Chemical Industries, Ibaraki 300-4293, Japan

Search for other papers by Y Date in
Google Scholar
PubMed
Close
,
K Toshinai Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Kiyotake, Miyazaki 889-1692, Japan
Department of Anatomy, Showa University School of Medicine, Tokyo 142-8555, Japan
Discovery Research Laboratories, Pharmaceuticals Research Division, Takeda Chemical Industries, Ibaraki 300-4293, Japan

Search for other papers by K Toshinai in
Google Scholar
PubMed
Close
,
T Kawagoe Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Kiyotake, Miyazaki 889-1692, Japan
Department of Anatomy, Showa University School of Medicine, Tokyo 142-8555, Japan
Discovery Research Laboratories, Pharmaceuticals Research Division, Takeda Chemical Industries, Ibaraki 300-4293, Japan

Search for other papers by T Kawagoe in
Google Scholar
PubMed
Close
,
T Tsuruta Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Kiyotake, Miyazaki 889-1692, Japan
Department of Anatomy, Showa University School of Medicine, Tokyo 142-8555, Japan
Discovery Research Laboratories, Pharmaceuticals Research Division, Takeda Chemical Industries, Ibaraki 300-4293, Japan

Search for other papers by T Tsuruta in
Google Scholar
PubMed
Close
,
H Kageyama Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Kiyotake, Miyazaki 889-1692, Japan
Department of Anatomy, Showa University School of Medicine, Tokyo 142-8555, Japan
Discovery Research Laboratories, Pharmaceuticals Research Division, Takeda Chemical Industries, Ibaraki 300-4293, Japan

Search for other papers by H Kageyama in
Google Scholar
PubMed
Close
,
Y Kawamura Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Kiyotake, Miyazaki 889-1692, Japan
Department of Anatomy, Showa University School of Medicine, Tokyo 142-8555, Japan
Discovery Research Laboratories, Pharmaceuticals Research Division, Takeda Chemical Industries, Ibaraki 300-4293, Japan

Search for other papers by Y Kawamura in
Google Scholar
PubMed
Close
,
S Shioda Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Kiyotake, Miyazaki 889-1692, Japan
Department of Anatomy, Showa University School of Medicine, Tokyo 142-8555, Japan
Discovery Research Laboratories, Pharmaceuticals Research Division, Takeda Chemical Industries, Ibaraki 300-4293, Japan

Search for other papers by S Shioda in
Google Scholar
PubMed
Close
,
Y Shimomura Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Kiyotake, Miyazaki 889-1692, Japan
Department of Anatomy, Showa University School of Medicine, Tokyo 142-8555, Japan
Discovery Research Laboratories, Pharmaceuticals Research Division, Takeda Chemical Industries, Ibaraki 300-4293, Japan

Search for other papers by Y Shimomura in
Google Scholar
PubMed
Close
,
M Mori Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Kiyotake, Miyazaki 889-1692, Japan
Department of Anatomy, Showa University School of Medicine, Tokyo 142-8555, Japan
Discovery Research Laboratories, Pharmaceuticals Research Division, Takeda Chemical Industries, Ibaraki 300-4293, Japan

Search for other papers by M Mori in
Google Scholar
PubMed
Close
, and
M Nakazato Department of Internal Medicine, Miyazaki Medical College, University of Miyazaki, Kiyotake, Miyazaki 889-1692, Japan
Department of Anatomy, Showa University School of Medicine, Tokyo 142-8555, Japan
Discovery Research Laboratories, Pharmaceuticals Research Division, Takeda Chemical Industries, Ibaraki 300-4293, Japan

Search for other papers by M Nakazato in
Google Scholar
PubMed
Close

Neuropeptide W (NPW) is a 30-amino-acid peptide initially isolated from the porcine hypothalamus as an endogenous ligand for the G protein-coupled receptors GPR7 and GPR8. An intracerebroventricular administration of NPW increased serum prolactin and corticosterone concentrations, decreased dark-phase feeding, raised energy expenditure, and lowered body weight. Peripherally, GPR7 receptors are abundantly expressed throughout the gastrointestinal tract; the presence of NPW in the gastrointestinal endocrine system, however, remains unstudied. Using monoclonal and polyclonal antibodies raised against rat NPW, we studied the localization of NPW in the rat, mouse, and human stomach by light and electron microscopy. NPW-immunoreactive cells were identified within the gastric antral glands in all three species. Double immunohistochemistry and electron-microscopic immunohistochemistry studies in rats demonstrated that NPW is present in antral gastrin (G) cells. NPW immunoreactivity localized to round, intermediate-to-high-density granules in G cells. NPW-immunoreactive cells accounted for 90% chromagranin A- and 85% gastrin-immunoreactive endocrine cells in the rat gastric antral glands. Using reversed-phase HPLC coupled with enzyme immunoassays specific for NPW, we detected NPW30 and its C-terminally truncated form, NPW23, in the gastric mucosa. Plasma NPW concentration of the gastric antrum was significantly higher than that of the systemic vein, suggesting that circulating NPW is derived from the stomach. Plasma NPW concentration of the gastric antrum decreased significantly after 15-h fast and increased after refeeding. This is the first report to clarify the presence of NPW peptide in the stomachs of rats, mice, and humans. In conclusion, NPW is produced in gastric antral G cells; our findings will provide clues to additional mechanisms of the regulation of gastric function by this novel brain/gut peptide.

Free access